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Article points
1. People with severe mental 
illness (SMI) are at increased 
risk of diabetes and experience 
more diabetes complications 
than those without SMI.
2. Antipsychotic medication 
can cause weight gain and 
metabolic disturbances 
that increase the risk of 
diabetes, although other 
factors also play a part.
3. The Lester resource provides 
a practical framework for 
assessing and managing 
cardiometabolic risk in 
people with SMI.
Key words
- Bipolar disorder
- Cardiovascular risk
- Diabetes
- Psychosis
- Severe mental illness
- Schizophrenia
Authors
Johanna Taylor is a Research 
Fellow, Mental Health and 
Addiction Research Group, 
University of York. David Shiers 
is a former GP and Honorary 
Reader in Early Psychosis, 
University of Manchester.
People with severe mental illness (SMI) have a reduction in life expectancy of around 
15–20 years. A higher prevalence of diabetes and its complications contributes to 
this health inequality. The risk of diabetes and barriers to managing the condition 
alongside SMI require more tailored lifestyle interventions, regular monitoring of risk 
from the onset of psychosis, high-quality antipsychotic prescribing, smoking cessation, 
support for self-management and collaborative care. Increasing awareness about the 
particular risks that people with SMI face and the proactive approach that is needed to 
sufficiently screen and intervene for diabetes may help to ensure that these individuals 
are better supported. The Lester resource provides practitioners with a useful tool to 
help facilitate this.
P
eople with severe mental illness (SMI; 
e.g. schizophrenia, bipolar disorder) have 
a reduction in life expectancy of around 
15–20 years. While suicide and accidents account 
for a quarter of premature deaths, most arise 
from illnesses that shorten lives in the general 
population, cardiovascular disease (CVD) being 
the single most common cause (Brown et al, 2010).
Diabetes is a particular concern, contributing 
to the morbidity and mortality gap and increasing 
the likelihood of premature CVD (Ward and 
Druss, 2015). Despite this, little is currently done 
to improve diabetes care in this population. This 
article aims to raise awareness about the particular 
risks that people with SMI face and the strategies 
that may help to better prevent and manage 
diabetes in this population.
Why is diabetes a problem for people 
with SMI?
Around 1% of the overall population per year 
experiences an SMI (Reilly et al, 2015). Psychotic 
features may include altered perceptions, thoughts, 
mood and behaviour, and can be highly distressing 
for the individuals and their family and friends. 
Some recover but the majority continue to 
experience difficulties. These include not only 
psychological difficulties but also poor physical 
health, which is often compounded by inequalities 
in healthcare (Ward and Druss, 2015).
Diabetes affects around 10–15% of people with 
SMI, a rate two to three times higher than in the 
general population (Reilly et al, 2015). Type 2 
diabetes accounts for most of the excess cases 
and typically commences 10–20 years earlier in 
those with SMI, the relative risk being highest in 
younger individuals (Holt and Mitchell, 2015). 
People with comorbid SMI and diabetes, when 
compared to those with diabetes alone, experience 
more diabetes complications (microvascular and 
macrovascular), and have a significantly increased 
risk of death (Vinogradova et al, 2010).
The path to premature diabetes and CVD may be 
heralded by the onset of psychosis and the initiation 
of antipsychotic treatment. Aggressive early weight 
gain, averaging 12 kg in the first 24 months of 
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treatment (Alvarez-Jiménez et al, 2008; Figure 1), 
increases the risk of future type 2 diabetes.
Other metabolic disturbances also increase 
the risk of type 2 diabetes in this population. 
A systematic review demonstrated significant 
glucose and lipid disturbance within 8 weeks of 
antipsychotic initiation, which worsened over 
the 12 months studied (Foley and Morley, 2011). 
Another review showed that antipsychotics could 
cause type 2 diabetes in people under the age of 
24 years (Galling et al, 2016).
Metabolic syndrome, which describes a 
clustering of CVD risks, reliably predicts a five-
fold increased risk of type 2 diabetes in the 
general population (Alberti et al, 2006). Prior to 
antipsychotic initiation, metabolic syndrome is no 
more likely in people experiencing a first episode 
of psychosis than in peers without psychosis 
(Fleischhacker et al, 2013). Yet by age 40 years, 
people with schizophrenia have a three-fold 
increased rate of metabolic syndrome compared 
with age-matched people from the general 
population (De Hert et al, 2006).
Although antipsychotic treatment plays 
an important role in increasing the risk of 
type 2 diabetes, to understand this population’s 
vulnerability to metabolic disturbance requires 
awareness of how psychosis impacts beyond 
simply the distress of symptoms and medication 
side effects. Social consequences, often profound, 
include damaged relationships and social 
isolation, stigma and discrimination, disrupted 
education and employment, and financial and 
accommodation uncertainties. SMI can also 
reduce motivation and cause paranoid thinking, 
and treatment side effects include sedation and 
appetite stimulation (Holt and Mitchell, 2015). 
Combined, these can influence lifestyles that 
predispose to type 2 diabetes, in particular physical 
activity, diet and smoking:
O Physical activity – fewer than 30% of people 
with schizophrenia are regularly active compared 
to 62% of their non-psychiatric peers (Lindamer 
et al, 2008). A systematic review found people 
with psychosis were sedentary for more than 
11 hours per day, 3 hours more than their non-
psychiatric peers (Stubbs et al, 2016).
O Diet – diet in people with SMI tends to be high 
in fat and refined sugar, low in dietary fibre 
and with inadequate fruit and vegetable intake 
(Dipasquale et al, 2013).
O Smoking – this is the single greatest preventable 
cause of premature death in people with SMI; 
smoking rates are two to three times higher than 
in the general population (Brown et al, 2010).
A list of cardiovascular risk factors in people 
with SMI can be found in Table 1.
What about healthcare?
Unfortunately, people with SMI do not always 
receive the care they need for their physical 
health. This inequality occurs for several reasons, 
-PN\YL>LPNO[NHPUVUHU[PWZ`JOV[PJTLKPJH[PVUMVSSV^PUNHÄYZ[LWPZVKLVMWZ`JOVZPZ
Data from Alvarez-Jiménez et al (2008). Published with permission from Prof. Alvarez-Jiménez.
RCT=randomised controlled trial.
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Schizophrenia Bipolar disorder
Risk factors Prevalence Relative risk Prevalence Relative risk 
Tobacco smoking* 50–80% 2–3 54–68% 2–3
Physical inactivity† 70% 2 No data No data
Obesity* 45–55% 1.5–2 21–49% 1–2
Hypertension* 19–58% 2–3 35–61% 2–3
Diabetes* 10–15% 2–3 8–17% 1.5–3
Dyslipidaemia* 25–69%  23–38% 
*Data from De Hert et al (2011). †Data from from Lindamer et al (2008).
Table 1. Cardiovascular risk factors for people with severe mental illness: 
Estimated prevalence and relative risk compared to the general population.
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including the lack of coordination and sharing 
of information between primary and mental 
healthcare providers, inadequate attention to 
physical health problems, limited understanding 
among healthcare professionals about the risk 
of diabetes and the challenges of managing 
diabetes alongside SMI, and barriers to accessing 
healthcare experienced by people with SMI 
due to their psychological, social and economic 
vulnerabilities (Mitchell et al, 2009; McGinty et 
al, 2015).
People with SMI describe primary care as 
the cornerstone of their physical and mental 
healthcare, and they especially value continuity 
and holistic approaches (Lester et al, 2005). 
However, annual GP consultation rates for people 
with SMI have plummeted from about 13 per year 
in the mid 1990s to around three per year more 
recently, only marginally higher than for the wider 
practice population. Additionally, practice nurses, 
who are key providers of health education and 
support for people with long-term conditions, are 
half as likely to see people with SMI as they are the 
wider population (Reilly et al, 2012).
Although annual physical health checks for 
people with SMI in primary care have been 
incentivised since 2004 as part of the Quality 
and Outcomes Framework (QOF), the National 
Audit of Schizophrenia (NAS) revealed that 
only 29% of 5091 people with this SMI had 
cardiometabolic risk (weight, smoking status, 
glucose, lipids and blood pressure) adequately 
assessed within the previous 12 months 
(Crawford et al, 2014). Moreover, only 53% of 
those found to have abnormal blood glucose levels 
had a record of appropriate intervention. The 
NAS found unacceptably wide variation in the 
prescribing of antipsychotics as well, including 
polypharmacy (multiple antipsychotic use, 
contrary to the evidence) and doses exceeding 
British National Formulary recommendations 
(Patel et al, 2014).
Inequalities in diabetes care may also contribute 
to poor outcomes in people with SMI and diabetes 
(Chwastiak et al, 2015). However, the evidence 
is unclear; some studies show that, compared to 
those with diabetes alone, people with SMI are 
less likely to be prescribed effective medications 
and tend to receive less monitoring and diabetes 
education. Other studies show no difference, while 
some suggest that people with SMI actually receive 
more diabetes care (Mitchell et al, 2009; McGinty 
et al, 2015). However, no research has investigated 
these healthcare inequalities in the UK (Ward and 
Druss, 2015).
What can be done? 
“Don’t Just Screen – Intervene”
Consider the following scenario:
Tim consults with you following your surgery’s 
invitation to attend for a check-up. He is 34 years 
old, has experienced schizophrenia for 10 years and 
receives a repeat prescription for an antipsychotic 
medicine. You check his blood pressure and enquire 
of his smoking and alcohol consumption, just as 
QOF incentivises. You can find no problems.  
Job done. Or is it?
Psychosis typically emerges in early adulthood, 
accelerating exposure to cardiometabolic risk 
below the age when primary care would normally 
consider active primary CVD prevention. 
Awareness of diabetes in people with SMI is also 
variable (Foley et al, 2016), and symptoms of 
psychosis can mask early indicators of metabolic 
disturbance.
Around 50% of cases of diabetes may go 
undetected in those with SMI (Foley et al, 
2016), compared with about 15% in the general 
population (Diabetes UK, 2015). In an Australian 
study, the authors screened 1153 adults with 
psychosis and found that 12% had type 2 diabetes 
and 19% were biochemically at high risk; however, 
54% of these participants were not previously 
aware of this, and awareness was lowest in the age 
group of 25–34 years (Foley et al, 2016). Failure 
to monitor this young at-risk population lies at the 
root of this health inequality.
The Lester resource (Figure 2) provides a 
practical framework for assessing and managing 
cardiometabolic risk in people with SMI. 
Developed in a process led by the late Professor 
Helen Lester, the resource has been endorsed by 
NICE, relevant Royal Colleges, Diabetes UK, 
NHS England and Public Health England. The 
Lester resource’s mantra, “Don’t Just Screen – 
Intervene”, highlights that, whilst identifying risk 
is essential, it is not sufficient in and of itself.
Page points
1. People with psychosis are 
typically exposed to increased 
cardiometabolic risk below 
the age when primary care 
would normally consider 
active primary cardiovascular 
disease prevention.
2. Despite this, less than a third 
of people with schizophrenia 
in the UK are receiving 
annual health checks to 
assess cardiometabolic risk.
3. Around 50% of diabetes cases 
go undetected in people 
with severe mental illness, 
compared to 15% of cases 
in the general population.
4. It is, therefore, essential 
not only to screen for 
cardiometabolic risk in this 
population but also to act in 
order to mitigate the risk.
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Let’s return to our scenario:
You decide to use the Lester resource. This means 
that, in addition to checking Tim’s blood pressure 
and enquiring about his smoking and alcohol 
consumption, you check his BMI and test his 
total/HDL cholesterol ratio and HbA
1c
. Tim’s risk of 
developing diabetes is now much clearer.  
Do you have all the information you need  
to intervene? And what’s next?
For the purpose of this article, let’s assume Tim’s 
BMI is 29 kg/m2 and his lipid results are normal. 
However, his HbA
1c
 results place him in the high-
risk category for diabetes. There are numerous 
interventions that may help Tim. But first and 
foremost you need to gain a holistic understanding 
of him, including both the personal challenges 
he may face in making lifestyle changes and the 
positive resources he might be able to access. A 
shared approach to decision-making is essential; 
intervention adherence and treatment outcomes 
are both enhanced when people are involved in 
decisions about their care (Hamann and Heres, 
2014). The interventions that may help Tim 
include the following.
Lifestyle interventions
NICE (2014) guidelines recommend that people 
with SMI who are at risk of diabetes should 
be offered lifestyle interventions. Systematic 
reviews show that these interventions can 
alleviate antipsychotic-induced weight gain 
and metabolic disturbances compared with 
routine care (McGinty et al, 2016). There is less 
understanding about the specific components and 
behaviour change techniques that lead to positive 
and sustainable lifestyle changes, and identifying 
suitable interventions tailored for people with SMI 
may therefore be a particular challenge.
Smoking cessation
A systematic review showed that smoking cessation 
interventions that work for the general population 
are equally effective for those with SMI (Banham 
and Gilbody, 2010), and a more recent study 
demonstrated that a bespoke intervention was 
acceptable to people with SMI and those who 
support them (Knowles et al, 2016). Currently, 
however, smoking cessation services are poorly 
suited to people with SMI, despite the fact that 
many who smoke wish to give up. For example, 
Page points
1. As with the general population, 
people with severe mental 
illness should be offered 
lifestyle interventions, which 
not only improve diabetes 
risk but also lessen the 
weight gain and metabolic 
disruption associated with 
antipsychotic medication.
2. Smoking cessation, the single 
most effective way to improve 
cardiometabolic risk, should 
be encouraged; however, 
currently in the UK, smoking 
cessation services are poorly 
suited to treat people with 
severe mental illness.
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FPG = Fasting Plasma Glucose | RPG = Random Plasma Glucose | BMI = Body Mass Index | Total Chol = Total Cholesterol | HDL = High Density Lipoprotein | TRIG = Triglycerides
Lester UK Adaptation | 2014 update
Positive Cardiometabolic Health Resource 
An intervention framework for people 
experiencing psychosis and schizophrenia
Glucose Regulation
Assess by fasting blood glucose (FPG); 
random blood glucose (RBG); HbA1c
HbA1C or Glucose threshold: 
HbA1C *42 mmol/mol (*6%)
AND / OR
FPG *5.5 mmol/l
OR
RPG * 11.1 mmol/l
Current smoker
Brief intervention
Combined NRT and / or 
varenicline
Individual / group 
behavioral support or 
specialist support if  
high dependency
Referral to Smoking 
Cessation service
Stop smoking
 Improve quality  
of diet
Contain calorie intake
Daily exercise of  
30 mins/day
BMI 18.5-24.9 kg/m2 
(18.5-22.9 kg/m2  
if South Asian  
or Chinese) 
<140/90 mm Hg
(<130/80 mm Hg for 
those with CVD or 
diabetes)
Prevent or delay  
onset of diabetes
HbA1c <42 mmol/mol 
(<6%)
 FPG <5.5 mmol/l
 HbA1c 47-58 mmol/mol  
(6.5-7.5%)
Follow  
NICE guidelines  
for obesity
http://www.nice.org.
uk/CG43
Follow NICE  
hypertension  
guidelines
http://publications. 
nice.org.uk/
hypertension-cg127
Consider anti-
hypertensive therapy
Limit salt intake in diet 
Diabetes
HbA1c *48 mmol/mol 
(*6.5%) 
FPG *7.0 mmol/l 
RPG *11.1 mmol/l 
Endocrine review 
Follow NICE  
diabetes guidelines
http://www.nice.org.
uk/CG87
Follow  
NICE guidelines  
for lipid modification
AND
Refer to specialist if  
total cholesterol >9,  
non-HDL chol >7.5 or 
TG>20 (mmol/l)
AND
Consider lipid 
modification for those 
with CVD or Diabetes
Poor diet
AND / OR
Sedentary lifestyle
BMI *25 kg/m2
(*23 kg/m2 if South  
Asian or Chinese)
AND / OR
Weight gain >5kg  
over 3 month period
>140 mm Hg systolic
AND / OR 
>90 mm Hg diastolic
Total chol/HDL ratio  
to detect high (>10%)  
risk of CVD based on 
QRISK-2 Tool
 http://qrisk.org/
Note: CVD risk scores  
can underestimate risk  
in those with psychosis 
At High Risk  
of Diabetes 
HbA1c 42-47 mmol/mol 
(6.0% - 6.4%)
FPG 5.5 - 6.9 mmol/l 
i)  Offer intensive 
structured lifestyle 
education  
programme
ii)  If ineffective  
consider metformin
Primary Prevention: 
consider Statin treatment 
if *10% risk based on 
QRISK2
OR
Secondary Prevention: 
aim to reduce non-HDL 
chol by 40% and review 
in 3 months
Smoking
Lifestyle and 
Life Skills
Body Mass  
Index (BMI)
Weight
Blood  
Pressure
Blood Lipids
Medication review and lifestyle advice to include diet and physical activity
Refer for investigation, diagnosis and treatment by appropriate clinician if necessary.
NB Family history of diabetes and/or premature heart disease heightens cardiometabolic risk. 
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About the Lester resource
The Lester resource provides 
a practical framework for 
assessing and managing 
cardiometabolic risk in 
people with severe mental 
illness. Developed in a 
process led by the late 
Professor Helen Lester, the 
resource’s mantra, “Don’t 
Just Screen – Intervene”, 
highlights that, whilst 
identifying risk is essential, 
it is not sufficient in and of 
itself.
The full framework is 
available to download at:
http://www.rcpsych.ac.uk/
quality/nas/resources
Figure 2. About the Lester resource.
Don’t Just Screen – Intervene: Protecting the cardiometabolic health of people with severe mental illness
Journal of Diabetes Nursing Volume 20 No 8 2016 301
stopping smoking can cause a rapid increase in 
blood levels of medications such as antipsychotics 
and certain antidepressants, and it may require 
accompanying dosage reductions (Banham 
and Gilbody, 2010). A useful guide to smoking 
cessation in people with SMI can be found at: 
http://bit.ly/2c25bdJ.
Antipsychotic medication
Careful antipsychotic selection and dosage 
is vital given these agents’ potential impact 
on cardiometabolic risk. It is important that 
prescribers in both primary and mental health 
settings provide clear information to patients about 
the risk of weight gain and metabolic disturbance. 
Treatment should be reviewed as a priority if there 
is rapid (e.g. <3 months) metabolic disturbance or 
weight gain (e.g. >5 kg in <3 months). Improving 
access to a dietitian at an early stage may help 
patients to make lifestyle changes alongside taking 
their medication. Considering an alternative 
antipsychotic medication associated with an 
improved metabolic profile may lessen these 
impacts (Mizuno et al, 2014), but any decision 
to change treatment should be carefully balanced 
against the risk of psychosis relapse and should 
always involve the patient’s psychiatrist.
Metformin
NICE (2012) already recommends use of 
metformin for the prevention of diabetes when 
other measures prove unsuccessful, and growing 
evidence suggests this agent may also lessen the 
weight gain and metabolic disturbance associated 
with antipsychotic medication (Mizuno et al, 
2014).
Monitoring risk
Monitoring risk is important for diabetes 
management as well as prevention. An annual 
diabetes check may help early detection of diabetes 
complications. This should include assessing for 
diabetes distress, which is correlated with poor 
diabetes control and comorbid depression (Snoek 
et al, 2015). For many people with diabetes, the 
annual check may be the only time they visit their 
GP. However, people with comorbid SMI may 
need more tailored and regular monitoring than 
this. For example, psychotic episodes or a change 
in antipsychotic treatment may increase CVD risk 
and impede efforts to maintain a healthy lifestyle.
Supporting self-management
Like the general diabetes population, people with 
SMI and diabetes need support for self-managing 
their diabetes.
Improving access to diabetes self-management 
education is essential; however, generic 
interventions may need to be tailored, for example, 
to address specific challenges such as poor locus 
of control, stigma and stress, motivational deficits 
affecting self-management, and limited social 
support (Blixen et al, 2016).
Care coordination
People with SMI and diabetes identify 
fragmentation of care as a key barrier to self-
management (Blixen et al, 2016). Poor continuity 
of care and limited sharing of information 
between different services are also identified as 
significant barriers. A collaborative approach to 
case management between primary and mental 
health services is needed; collaborative care 
models consistently show improvements in health 
outcomes for people with depression and comorbid 
physical illness (Coventry et al, 2014).
Conclusions
People with SMI currently receive inferior care 
for diabetes, partly as a result of inequalities 
in healthcare provision but also because their 
exposure to risk and the challenges they face 
in accessing appropriate care mean that a more 
tailored and intensive approach is required. 
Primary care is ideally placed to tackle this 
health inequality. Nurse practitioners have the 
necessary skills and knowledge to proactively 
manage cardiometabolic risk and, moreover, are 
well placed to coordinate management of detected 
abnormalities within the low-stigma setting of 
primary care.
Let’s return a final time to our scenario:
Having established that Tim is at high risk of 
diabetes, you refer him to a lifestyle intervention, 
which includes regular physical activity and 
nutritional counselling. You also arrange for 
him to see his GP to review his antipsychotic 
Other useful resources
http://bit.ly/2bRSkx9
www.nice.org.uk/
guidance/cg178
http://bit.ly/2c25bdJ
FACT FILE 13
Compared with the general population, men with schizophrenia 
die, on average, 20.5 years earlier, and women who have the 
condition 16.4 years earlier. One-third of these premature 
deaths are attributed to suicide or injury but the rest are from 
physical causes, and particularly from cardiovascular disease 
(CVD). The rates of CVD are two to three times higher in this 
group than in the general population. The reductions in 
cardiovascular morbidity and mortality seen in the general 
population over the last two decades have not been enjoyed 
by people with severe mental illness. Cardiovascular disease 
is the single biggest contributor to the premature death of 
people with severe mental illness and the main cause of the 
mortality gap between this group and the general population.  
While clarity over the precise nature and relative contribution  
of genetics, demographic effects and adverse effects from 
antipsychotic medicines is lacking, what is evident is that 
adverse cardiometabolic risks can appear within weeks  
of commencing treatment. Lifestyle issues and social 
determinants then convert vulnerability into ill health and 
premature death.
Risk of diabetes, and other antecedents of CVD  
in severe mental illness
People with severe mental illness have raised rates of 
modifiable CVD risk factors, namely: smoking, obesity, 
diabetes, hypertension, dyslipidaemia and metabolic 
syndrome. Around 10–15 per cent of those on antipsychotic 
medication develop Type 2 diabetes (a rate two to three times 
higher than in the general population). Genetic links between 
diabetes and schizophrenia have long been recognised. In his 
1897 text, The Pathology of Mind, Sir Henry Maudsley noted: 
‘Diabetes often shows itself in families in which insanity 
prevails’. These higher rates of diabetes are almost entirely 
accounted for by Type 2 diabetes. As many as 70 per cent  
of cases are undiagnosed, compared with 25 per cent in the 
general population. A European study screening people  
with schizophrenia who were not known to have diabetes, 
discovered 10 per cent had diabetes and 38 per cent were  
at high risk of diabetes; moreover, this population’s average 
age was only 38 years.
Studies show that lipid abnormalities are common, affecting 
25–69 per cent of those with severe mental illness, and may 
be partially linked to use of antipsychotics. Typical changes 
include raised low density lipoprotein cholesterol and 
triglycerides, and decreased high density lipoprotein  
cholesterol. Similarly, hypertension is also more common 
although, sometimes, the pharmacological effects of 
antipsychotics can mitigate blood pressure elevation.  
Finally, around 70 per cent of people with schizophrenia 
smoke, compared with 22 per cent of the general population. 
Antipsychotic medication  
Second generation, or atypical, antipsychotic drugs have been 
introduced over the last 15 years with the hope that they 
would replace less effective and more poorly tolerated older, 
first generation medicines. It is increasingly clear that this hope 
was misplaced. While the newer agents are associated with a 
lower risk of movement disorders, some are more likely to 
cause metabolic side effects, including significant weight gain. 
Furthermore, a lack of high-quality research and over-reliance 
on short duration trials involving people with established 
illness, many of whom may already have gained weight from 
previous antipsychotic exposure, may have led to a three- to 
fourfold underestimate of weight gain in people exposed to 
antipsychotics for the first time.
The European First Episode Schizophrenia Trial (EUFEST) 
is a high-quality study that examined the issue of weight gain 
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MENTAL HEALTH
Living well for longer
Primary Care Guidance on  
Smoking and Mental Disorders 
KEY LEARNING POINTS »  Smoking is the largest avoidable cause of  
premature death and health inequality in  
those with mental disorders who die 10-20  
years earlier than the general population. 
»  Adults with mental disorders consume 42% of  
the tobacco in England and therefore dispropor-
tionately experience tobacco related harm.
»  With appropriate support, people with mental 
disorder are able to stop smoking.
»  Smoking cessation improves mental and physical 
health even in the short term and reduces risk of 
premature death. 
»  Impact of smoking cessation on mood and anxiety 
disorders is at least as large as antidepressant 
treatment.
»  Stopping smoking requires the immediate  
reduction of doses of some antidepressants, 
antipsychotics and benzodiazepines by up to 25% 
within the first week and up to 50% within 4 weeks.
Smoking: the biggest killer 
Smoking is the largest cause of preventable 
death in England. In 2010/11 it was 
responsible for 79,100 deaths and 459,900 
hospital admissions 1. Smokers die an 
average 10 years earlier than non-smokers 2. 
Smoking is also associated with an increased 
risk of several chronic diseases, including 
cardiovascular disease, peripheral arterial 
disease with associated 10-16 fold increased 
risk of amputation3, chronic obstructive 
pulmonary disease and type 2 diabetes  
(60% increased risk4) as well as cancer, 
blindness and dementia.
Smoking is therefore one of the most 
important modifiable risk factors for both 
premature mortality and chronic disease.  
This is even more important in people with 
mental disorder since smoking is the single 
largest contributor to their 10-20 year  
reduced life expectancy 5,6,7,8. 
Higher rates of smoking in 
people with mental disorders 
People with mental disorders experience 
disproportionate levels of smoking associated 
harm since they are both more likely to  
smoke and to smoke more heavily than the 
general population. In England, 42% of 
tobacco consumption is by those with  
mental disorders 9 while 43% of smokers 
aged 11-16 have either conduct or emotional 
disorders 10.
Compared to 20% smoking rates in the adult 
population, smoking rates are higher for 
people with different mental disorders: 
UÊ 
ÊiÌ>Ê`ÃÀ`iÀ\ÊÎÓ¯Ê 
(27% for those on antidepressants  
and 30% for those on anxiolytics) 11 
UÊ *ÃÞVÃÃ\Ê{ä¯Ê9 (59% of people with  
a first episode of psychosis and 59%  
of those taking antipsychotics) 11
UÊ ÀÕ}Ê`i«i`iVi\ÊÈ¯9
UÊ VÊ`i«i`iVi\Ê{È¯9 
UÊ -ÕV`iÊ>ÌÌi«ÌÊÊ«>ÃÌÊÞi>À\ÊxÇ¯9
UÊ «>ÌiÌÃÊÊiÌ>Êi>ÌÊÕÌÃ\Ê 
70% (50% are heavy smokers13)
Compared to smoking rates of 5% among 
11-16 year olds in the general population, 
smoking rates are10 :
UÊ Îä¯Ê>}ÊÌiÊÈ¯ÊvÊ£££ÈÊÞi>ÀÊ 
olds with conduct disorder
UÊ £¯Ê>}ÊÌiÊ{¯ÊvÊ£££ÈÊÞi>ÀÊ 
olds with emotional disorder
Smoking is the single largest cause of the 10-20 year lower  
life expectancy of people with mental disorders.
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medication. Tim has a care coordinator as part of 
the care he receives from specialist mental health 
services. You share information about Tim’s risk 
of diabetes so that the coordinator can also help to 
support him as he makes lifestyle changes.
Increasing awareness about the particular risks 
that people with SMI face and the proactive 
approach that is needed to sufficiently screen 
and intervene for diabetes may help to ensure 
that individuals are better supported. The Lester 
resource provides a useful tool to facilitate this. 
However, only recently has policy and research 
prioritised this health inequality, and tailored 
diabetes interventions for this population are still 
lacking. We hope the current focus on improving 
diabetes prevention and management for people 
with SMI will increase the opportunities to 
intervene as well as to screen. Q
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